From the Producers of

2nd International Conference & Exhibition

Drug Discovery Technology®

FR

Cocktail Su EE for first 100 nset Cruise registratio ns! See details inside!

China 2007 R&D Summit Partnering, Licensing & Outsourcing from R&D to Clinical Trials June 4-7, 2007 • Grand Hyatt Hotel • Shanghai China Integrate China into Your Global Strategy – from R&D to Clinical Trials Hear first-time case studies, industry insights and exciting panel discussions on controversial topics to help you leverage China as your global partner in licensing, outsourcing or joint research and development.

Gain Insider Perspectives on How Companies are Leveraging Drug Discovery Partnerships in China

Learn from Past Successes in Regional Partnerships & Experiences

• Pharmaceutical R&D in China: Leveraging Collaboration & Managing Risk for Maximum Value: Eli Lilly & Company • Me2 Drug Discovery: China Experience: Shanghai HengRui Pharmaceuticals

Get a Head Start on Your Development Strategies with Insights on Preclinical Safety Pharmacology in China • T he Birth Of US Level GLP Compliance Drug Testing in China and Its Implications for Future Global Drug Development: Bridge Pharmaceuticals

•G  lobal Partnering in Pharma R&D: The question is not China OR India, but China AND India: Novartis Pharma AG • E merging Intellectual Life-Science Properties in Asia the Boehringer Ingelheim In-Licensing Approach: Nippon Boehringer Ingelheim

Examine the Landscape and Intricacies of Clinical Trials in China to Improve Your Chances of Success •P  atient Recruitment - Requiring New Skills and Mindset from Clinical Research Staff: GSK China Pharmaceuticals • Optimizing Return on Investment (ROI) of Multinational and Domestic Clinical trials in China: Bayer Healthcare Co. Ltd. • Building Clinical Trial Infrastructure in General Hospitals: Abbott Laboratories

•C  ase Studies on PreClinical Development and Outsourcing: Sirtris Pharmaceuticals, Amgen, Eli Lilly etc.

Stay Ahead of Your Competition with First-Hand Knowledge on Licensing Strategies and Trends

Hear about The Rise of Biotechnology in China and the New and Unique Biotech R&D Business Models

• T he Fall of Global Licensing - The Rise of Regional Licensing?: AstraZeneca • I mproving Your Out-licensing Opportunities to Foreign Partners – What Chinese Companies Need To Do: DebioPharm

• T he Rise of China’s Biotech and Opportunities for Partnership: GeneScience Pharmaceuticals Co. Ltd •M  aking Innovative Medicines Faster and Cost-Efficiently: Ascenta Therapeutics

PLUS! Optional Pre-Conference Workshop, June 4, 2007, 8:30am – 12:30pm

GLP in China: Current and Future Prospects

This workshop will review the state of the art of preclinical GLP practices in China, and how they currently compare from a technical and regulatory perspective to the US and EU. Topics will include a survey of the critical components of and differences in IND’s; proficiency testing, training and certification; animal supply; differences and similarities in QA (including bioinformatics); as well as current toxicology and bioanalytic practices in China compared to current western practices. See inside for more details!

Organized by:

Shanghai Zhangjiang (Group)Co.,Ltd 上海张江（集团）有限公司

Gold Sponsor:

IBC USA Conferences, Inc. IBC ASIA (S) PTE LTD IBC Conference and Event Management Services (Shanghai) Co., Ltd

Silver Sponsor:

Corporate Sponsor:

Featured Sponsor:

Session Sponsor:

Bronze Sponsors:

Premier Publication

Association Partners:

Silver & Luncheon Sponsor:

Register Early & Save – www.IBCLifeSciences.com/China



2nd International Conference & Exhibition Drug Discovery Technology®

China 2007 R&D Summit Keynote & Featured Speakers

Phil Vickers, Ph.D. VP & Site Head, Research Technology Pfizer Inc.

C. David Nicholson, Ph.D.

Lei Jin, Ph.D.

Jean Deregnaucourt, Ph.D.

Samantha Du, Ph.D.

Executive Vice President, R&D Organon International

Zhaohui Peng, Ph.D.

Chairman SiBiono GeneTech Co. Ltd., China

Chief Executive Officer GeneScience Pharmaceuticals Co. Ltd

Vice President Pierre Fabre Laboratories, S.A., France

CEO Hutchinson Medipharma

IBC’s 2nd International Drug Discovery Technology® Conference & Exhibition: China 2007 R&D Summit provides a not to be missed opportunity for Western and Chinese companies to come together to explore potential business collaboration opportunities in China’s fast growing life sciences industry.

For wholly-owned Chinese companies, this is the time to showcase your capabilities in biology, chemistry, preclinical and clinical development, and to open your doors to potential collaboration with foreign partners and investors to further spur your growth in the market.

The event offers a platform for international companies to better evaluate the cost savings in perspective of the quality and capabilities of the Chinese companies, while at the same time, solidifying their strategies for entering into the billion dollar pharmaceutical market in China through licensing, outsourcing, joint venture or M&A.

Through keynote presentations, industry insights, first-hand case studies and engaging panel discussions, the event aims to bring together experts from US, Europe, China, Japan and rest of Asia, to share success stories and winning strategies on how you can integrate these partnerships into your global R&D strategy!

Monday, June 4, 2007 Pre-Conference Workshop: GLP in China: Current and Future Prospects

Tuesday, June 5, 2007 Plenary Session I: P hil Vickers, Ph.D., VP & Site Head, Pfizer Inc. Zhaohui Peng, Ph.D., Chairman, SiBiono GeneTech Co.,Ltd. En Li, Ph.D., Vice President, Novartis Institute of Biomedical Research and Head, Novartis Research China VC Investment and M&A in China Plenary Session II: C  . David Nicholson, Ph.D., EVP, R&D, Organon International Jean Deregnaucourt, Ph.D., VP, Pierre Fabre Laboratories, S.A. Track I: Track II: Drug Discovery Partnerships in China Building Biopharmaceuticals in China Cocktail Reception in Exhibit Hall Gala Dinner (optional)

Wednesday, June 6, 2007 Track I: PreClinical Safety Pharmacology in China

Track II: China Law Update, Licensing Strategies Regional Experiences

Clinical Trials Cocktail Sunset Cruise (Free for first 100 registrations)

Thursday, June 7, 2007 The Rise of Biotechnology in China Site Visit (Free for first 100 registrations)

E-mail: [email protected]• Call: (+65) 6514-3180 • Fax: (+65) 6733-5087

2



Pre-Conference Workshop 

Monday, June 4, 2007 • 8:30am – 12:30pm

GLP in China: Current and Future Prospects

Sponsored by

Chairperson: Ron Marler, D.V.M.,Ph.D., Associate Director for Research and Professor, Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Arizona (former Vice-President, Marion Merrell Dow Pharmaceuticals and Vice-President, North America Toxicology, Covance Laboratories) (invited)

More and more preclinical and clinical studies are being undertaken in China, and more and more of these data are being incorporated into global submissions. Ideally harmonizing processes across China, EU and the US could greatly facilitate industry efficiencies and provide for a strong rationale for growth of the CRO sector development in China. An obvious critical aspect is achieving valid lab analysis results with valid conclusions using validated processes that are acceptable to global regulatory standards. This workshop will review the state of the art of preclinical GLP practices in China, and how they currently compare from a technical and regulatory perspective to the US and EU. Topics will include a survey of the critical components of and differences in IND’s; proficiency testing, training and certification; animal supply; differences and similarities in QA (including bioinformatics); as well as current toxicology and bioanalytic practices in China compared to current western practices. An important and emerging role exists for GLP outsourcing of drug development to China, and this workshop is meant to comprehensively survey its current status and future potential.

Overview of GLP in China SFDA Director General (invited)

A Critical Examination of IND Regulations and Procedures in the US, EU and China Ada Kung, DABT, Ph.D., Bridge Pharmaceuticals

Overview of Important OECD GLP Regulations as Potentially Practiced in China Francica Liem, Ph.D. OECD Working Group Chairperson

Global Training Programs for Harmonized US-EU-CHINA GLP Carol Spicer-Nair, Bridge Pharmaceuticals

Facilities Systems Validation and Metrology Tom Lue, Ph.D., Bridge Pharmaceuticals

Quality Animal Supply in China Shengming Lu, Vital River, Ltd.

Implementation of Global Compliant GLP in China: QA Jim Carignan, BS RQAP-GLP, Bridge Pharmaceuticals

Implementation of Global Compliant GLP in China: Toxicology Julie Lin, RQAP- GLP, Bridge Pharmaceuticals

Implementation of Global GLP in China: Bioanalysis Michael Zou, Ph.D., Bridge Pharmaceuticals

Summary & Conclusion: Similarities and Differences in GLP Practices and Its Impact – SFDA vs. FDA Li Jie Fu, Ph.D., Bridge Pharmaceuticals

3

To Register, Web: www.IBCLifeSciences.com/China



Main Conference 

Tuesday, June 5, 2007

7:00 Registration and Welcome Coffee/Tea

Plenary Session I 8:30 Opening Remarks by IBC USA Conferences

VC Investments and M&A 11:00 VC Investments & M&As in China – Understanding the State of the Industry in the Eyes of Investors

8:50 Plenary Lecture I Global Drug Discovery Partnerships – From Technologies to Therapies

PANEL DISCUSSION

8:40 Welcome Remarks by Zhangjiang Group

• Where are the investible segments in China? Are there NCE/novel therapeutic development for investment? What's missing in China's life sciences' space? • Valuation of Chinese life science companies - is it too hot? • M&A or IPO? How do you establish liquidity in an investment? What are the exit strategies? • Where is the local VC community? Are there people who can really incubate or grow companies into investible entities? Moderator:Stephen Knight, M.D., Managing Partner, Fidelity Biosciences Panelists: Brian Hargreaves, Ph.D., Sector Partner, 3i plc. Jimmy Zhang, Ph.D., MBA, Vice President, Business Development, Synergenics, LLC. Y. James Li, M.D., Partner, Kleiner Perkins Caufield & Byers Brian Doyle, Principal & Investment Banker, European and Asian Investment Banking, William Blair & Company

9:20 Plenary Lecture II The Current State of Gene Therapy in China

11:50 MIV Therapeutics' Acquistion and R&D Strategies in China

8:45 Chairperson’s Opening Remarks

Li Chen, Ph.D., Head of Research & CSO, Roche China R&D Center

To aid in the successful prosecution of a broad drug discovery portfolio, Pfizer has established a wide range of external investments across the globe with academic institutions and biotechnology companies. These include investments to develop cutting edge technologies with broad utility, in addition to partnerships focused on specific therapeutic targets. Key elements of this strategy will be reviewed, in addition to discussing critical features for successful partnerships. Phil Vickers, Ph.D., VP & Site Head, Research Technology, Pfizer, Inc

China is one of a very few countries that have approved and performed gene therapy clinical trials during the early 1990s. China actually is very advanced in the commercialization of gene therapy products as demonstrated by Gendicine, which has been administered to more than 4000 patients from various ethnic backgrounds with 50 different cancer indications. A variety of gene therapy research endeavors are currently under way in China, and many of them focus on anti-cancer gene therapy. Undoubtedly, China will be the pioneer of innovation and development of gene therapy research. Zhaohui Peng, Ph.D., Chairman, SiBiono GeneTech Co. Ltd.

9:50 Plenary Lecture III Incorporating China as part of Novartis' Global R&D Strategies

Abstract not available at time of print. Please visit www.IBCLifeSciences. com/China for updates. En Li, Ph.D., VP, Novartis Institute of Biomedical Research, Head, Novartis Research, China

10:20 Opening of Exhibit Hall and Morning Refreshments in Exhibit Hall

Abstract not available at time of print. Please visit www.IBCLifeSciences. com/China for updates. Mark Landy, Ph.D., President & CEO, MIV Therapeutics

12:15 Life Sciences M&A and VC Investment Trends and Developments in China

• US company setting up WOFE in China to outsource R&D • Hiring Chinese employees, stock options, termination, and reasonable non-compete clauses • Patent application; enforcement of IP rights • Arbitration of disputes • Turn into a joint venture • Are industry or business activities restricted industries that prohibit direct foreign ownership investment • M&A and VC investment in Chinese entities • Due diligence of Chinese companies • Redchip redomicle (offshore holding vehicle) • Need for SAFE approval • Round trip investment • September 8, 2006 Foreign Funded M&A of Domestic Enterprises discussion and implication, need for MOF approval Simon Luk, J.D., Partner, Heller Ehrman

12:40 Strategic Trade

Pharmaceutical manufacturers increasingly are pursuing partnering opportunities in China. Whether it’s contract R&D, manufacturing, or clinical trials, executives at the corporate and local level are facing questions about the impact on their logistics, finance, tax, and R&D departments of the cross-border movement of their ideas, materials, goods, and services Speaker to be confirmed, Pharmaceutical Leader, Ernst & Young

1:05 Networking Luncheon sponsored by

E-mail: [email protected]• Call: (+65) 6514-3180 • Fax: (+65) 6733-5087

4



Main Conference 

Tuesday, June 5, 2007 (continued) 3:15 Current Trends in Pharma Discovery and Biology Research in China

Plenary Session II 2:10 Chairperson’s Opening Remarks

Ying Luo, Ph.D., President and CEO, Shanghai Genomics, Inc.

Organon’s focus and discovery is to maximize the quality of our research output at competitive costs. To do this we need to collaborate with research groups worldwide. The burgeoning boom in biotech in China offers a highly attractive source for collaborative efforts. During my presentation I will describe our collaborations with companies such as HD Biosciences, Shanghai Genomics and ChemPartner. C. David Nicholson, Ph.D., Executive Vice President, R&D, Organon International

2:45 Plenary Lecture V Chinese and French Converging interest in Traditional Chinese Medicine Research and Development: The Case of Pierre Fabre Laboratories Partnerships

Over the past years, Pierre Fabre Laboratories set up partnerships with Chinese counterparts on key steps of the entire Research and Development process. Several partnerships aim at finding and studying the active ingredients and some others are dedicated to improve the formulation of traditional Chinese medicines. Jean Deregnaucourt, Ph.D., Vice President, Pierre Fabre Laboratories, S.A.

PANEL DISCUSSION

2:15 Plenary Lecture IV Organon’s Exploration in China

• Biology is still on the rise and can it meet the standards required by eg western pharmaceutical companies? • How that efforts can be integrated into current efforts in big pharma... how to integrate whole process of drug discovery, on a global sense.... when should you get in, how much should you get in, where is the money. • Current state of drug discovery in China – from me-2 drugs to innovative medicines. • Contract research – vehicle for Chinese pharmas to expand their R&D expertise and quality levels, and a bridge for them to enter global markets. Moderator: Li Chen, Ph.D., Head of Research & CSO, Roche China R&D Center Panelists:  Richard Soll, Ph.D., Chief Scientific Officer, TargeGen Yuanwei Chen, Ph.D., Chief Scientfic Officer, Egret Pharmaceuticals Dajun Yang, Ph.D., Senior Vice President, Research, Ascenta Therapeutics Inc. Ying Luo, Ph.D., President and CEO, Shanghai Genomics, Inc. Steve Q. Yang, Ph.D., Head of Research, Asia (ex Japan), Pfizer

4:00 Afternoon Refreshments in Exhibit Hall

TRACK I: Drug Discovery Partnerships in China

TRACK II: Building Biopharmaceuticals in China

Chairperson: Ying Luo, Ph.D., President and CEO, Shanghai Genomics, Inc.

Chairperson: Kewen Jin, M.D., CEO, Shanghai BioExplorer Co. Ltd

4:45 Pharmaceutical R&D in China: Leveraging Collaboration & Managing Risk for Maximum Value

4:45 Technology Workshop CrossFire - Today's Usage and Opportunities for Medicinal Chemists

5:10 Me2 Drug Discovery: China Experience

5:10 Case Study: Building and Growing a Wholly-Owned Chinese Subsidiary: Challenges & Triumphs

Abstract not available at time of print. Please visit www.IBCLifeSciences.com/China for updates. Guoxin Zhu, Ph.D., Head, China Research, Discovery Chemistry Research & Technology, Eli Lilly & Company

Abstract not available at time of print. Please visit www.IBCLifeSciences. com/China for updates. Jochen Tannemann, Product Manager, Elsevier MDL

New drug discovery has been mostly carried out in state-run high research institutions. As generic drugs market in China has become increasingly competitive, research and development on IP protected affordable medicines are the next frontier for China pharmaceutical companies. The experience of building up of an 100 plus chemistry driven drug discovery team as compared with that of a US biotech company will be discussed as will be several Me2 research programs. Tang Peng Choo, Ph.D., Chief Scientific Officer, Shanghai Hengrui Pharmaceuticals

5:35 A New Alliance-Based Model for R&D: The ShanghaiToronto Institute for Health Research

The Shanghai-Toronto Institute for Health Research (STIHR) is a collaboration between the University Health Network (Canada’s largest research hospital), its wholly owned subsidiary in Shanghai, and two research institutes in Shanghai: Institute of Health Sciences (IHS),and Shanghai Institute of Organic Chemistry (SIOC). Launched in 2006, STIHR integrates the complementary strengths of its partners towards the ultimate goal of bringing new drug candidates to the clinic. Christopher J. Paige, Ph.D., Vice President, Research, University Health Network

6:00 Cocktail Reception in Exhibit Hall Sponsored by

5

and

Outsourcing and establishment of subsidiary/JV in China are becoming popular among western biotech and pharmas. Cost reduction and gaining market access are among the top reasons. Although, it is easy to comprehend strategically, at operational level, it can be challenging and could lead to very different outcomes. Focusing on operation details is key to success with this approach. Peter Li, Ph.D., Senior Vice President of Product Development and Head of China Operations, Epitomics, Inc.

5:35 Shanghai United Pharmatech's Strategies and Steps towards Meeting GMP Requirements

United Pharmatech, an outsourcing service company, offers global pharmaceutical company’s diverse custom synthesis, process R&D and scale-up production of clinical intermediates and APIs required in cGMP environment. Strategies and steps towards meeting GMP requirement will be discussed and case study for successful delivery of clinical API will be presented. United Pharmatech’s business model has proved it is suitable for US pharmaceutical and biotech companies to outsource their clinical API production to Chinese service companies to reduce their R&D cost. Xiongwei (Shawn) Shi, Ph.D., Chief Executive Officer, Shanghai United Pharmatech

7:30 Gala Dinner (optional)

Enjoy a sumptuous dinner, prepared by the Grand Hyatt’s top chefs while chatting with old acquaintances and potential new partners. Space is limited and additional fee applies. Check box on registration page to sign up.

To Register, Web: www.IBCLifeSciences.com/China



Main Conference

Wednesday, June 6, 2007

TRACK I: PreClinical Development & Safety Pharmacology in China

TRACK II: 8:30 Chairperson’s Opening Remarks

Lorenz Ng, M.D., Vice President, Research Alliances and Business Development, Eli Lilly & Company

Chinese Pharmaceutical Law Update Sponsored by

8:40 Patent Issues Facing Pharmaceutical Companies in China

Glenn Rice, Ph.D. CEO and President, Bridge Pharmaceuticals

8:30 The Birth Of US Level GLP Compliance Drug Testing in China and Its Implications for Future Global Drug Development

This talk will summarize the state of the art of China preclinical drug development outsourcing industry and examine the critical components of facilities and equipment; bioinformatics; animal supplies and welfare policies; logistics and project management; training and certification; costs and productivity; related intellectual property protection issues; and understanding and implementation of quality assurance and US FDA GLP regulations and how these compare to the SFDA. Many biopharmaceutical companies are becoming increasingly comfortable with the rationale (and in fact ultimate necessity) of a China development plan, and an important and emerging role exists for outsourcing GLP compliant preclinical drug development to China. Glenn Rice, Ph.D. CEO and President, Bridge Pharmaceuticals

8:50 Overview of Important OECD GLP Regulations as Potentially Practiced in China

Francica Liem, Ph.D., OECD Working Group Chairperson

PANEL DISCUSSION

9:10 Safety Pharmacology in PreClinical Drug Development of Small Molecules Pharmaceuticals and Biotherapeutic Proteins

• Safety Pharmacology is one of the core safety components for IND and eIND submission and also widely used for early phase drug screening. It was regulated with ICH S7A and S7B. • Introduction of essential concepts of safety pharmacology and addressing the technical concerns and implementation in China. • Comparison of GLP laboratories in China vs. USA • Primate Testing Facilities and Services Moderator: Glenn Rice, Ph.D., President & CEO, Bridge Pharmaceuticals Inc. Panelists: Danong Chen, Ph.D., Chief Executive Officer, Tanox Inc. Yi Yang, Ph.D., M.D., Associate Director, US Head, Safety Pharmacology, Novartis Pharmaceutical Corporation Rakesh Dixit, Ph.D., DABT, Senior Director & Global Head, Toxicology Department, MedImmune, Inc.

10:00 Case Study: PreClinical Drug Development Opportunities in China

Abstract not available at time of print. Please visit www.IBCLIfeSciences. com/China for updates. Samantha Du, Ph.D., Chief Executive Officer, Hutchison Medipharma

10:25 Morning Refreshments in Exhibit Hall

11:15 Preclinical Experiences

Abstract not available at time of print. Please visit website for updates. Jian Luo, M.D., Principal Scientist, Amgen Inc.

PANEL DISCUSSION

8:25 Opening Remarks by Chairperson

Focus on the current intellectual property law regime affecting pharmaceutical companies (both multinationals and generics) doing business in China and how the Third Amendment of the Patent Law will affect such companies. Discussion on the gathering of evidence in pharmaceutical patent infringement cases and the reversal of burden of proof under Article 57 of the PRC Patent Law. Claire Robley, B.A., M.A., Associate, Intellectual Property, Bird & Bird Sofia Chen, Associate, Intellectual Property, Bird & Bird Zhaohui (Zoe) Wang, Attorney, Perkin Coie Anthony Chen, Jones Day

Licensing Strategies and Opportunities 9:30 The Fall of Global Licensing – The Rise of Regional Licensing?

Cut-throat competition between licensing partners and the recognition that most global partners have regional strengths has seen an increase in the number of regional licensing deals. What does this mean for licensors and licensees? Using examples of recent deals executed in AsiaPacific, we will see that this has implications for how we build our BD agendas, execute transactions and manage our partnerships. Carl A J M Firth, Ph.D., Regional Business Development & Strategic Planning Director, Asia-Pacific, AstraZeneca

9:55 Improving Your Out-licensing Opportunities to Foreign Partners – What Chinese Companies Need To Do Since its participation to WTO, China no longer can rely on its own territory for its R&D biomedical and biotechnological projects. There is need to have a global world market vision for all innovative drugs. Licensing out an R&D project for territories outside of China remains the best choice for Chinese companies. The procedures for out-licensing usually happen in two phases: scientific evaluation and establishment of collaboration agreement.Scientific evaluation must begin with a "Confidential Disclosure Agreement", which will allow scientific information to be exchanged. Given the differences between Chinese registration policies and FDA or EMEA procedures, elaborating presentation files remains a gap for Chinese companies Li-Ya Ju, Ph.D, Associate Director, China Relations, DebioPharm

10:20 Morning Refreshments in Exhibit Hall

Regional Partnerships & Experiences 11:15 Case Study of a Successful R&D Collaboration in China This presentation will discuss a successful collaboration in medicinal chemistry between Shanghai ChemPartner from China and Curis, Inc. from USA, which has helped to accelerate Curis' discovery and development pipeline of drug candidates. It will introduce lessons learned through the collaboration, practical experiences conducting R&D in China and analyze success factors for a fruitful collaboration. Michael Hui, Ph.D., Chief Executive Officer, Shanghai ChemPartner Co., Ltd.

E-mail: [email protected]• Call: (+65) 6514-3180 • Fax: (+65) 6733-5087

6



Main Conference

Wednesday, June 6, 2007 (continued) TRACK II:

TRACK I: 11:40 Outsourcing in China for a Small Biotech: Pros and Cons

11:40 Licensing and Collaboration Strategies of Japanese Pharmas

12:05 Safety Assessment of Biologicals Produced in Mammalian Cells Required for Clinical Trials and Marketing

12:05 The Question is Not China OR India, but China AND India

Utilizing CROs outside the US is an attractive financial option. The cost of chemical synthesis, protein production and preclinical studies are all cheaper. However, the cost of managing such efforts should be taken into consideration. This talk will weigh the pros and cons of such a decision. Peter Elliott, Ph.D., Senior Vice President, Head of Development, Sirtris Pharmaceuticals Inc.

To ensure the safety of the public, demonstration that biologicals intended for human use are free of adventitious agents (such as viruses) is required by regulatory agencies. A strategy composed of three independent yet complementary approaches is commonly employed in the biotech industry to achieve the safety assurance. Details of the strategy and technologies involved in its execution will be shared and discussed. Dayue Chen, Ph.D., Principal Research Scientist, Eli Lilly & Company

12:30 A Critical Evaluation of PreClinical Services in China and How Chinese Companies Can Enhance Partnership Opportunities

Abstract not available at time of print. Please visit www.IBCLifeSciences. com/China for updates. Diana Galer, Ph.D., Vice President, Drug Safety Research & Development – Operations, Pfizer Inc.

Japanese pharmaceutical companies have gradually changed due to globalization in pharmaceutical business, clinical development and collaboration. I would like to briefly summarize the present situation and their interests & strategies. Then I will propose how to communicate with several types of Japanese pharmas in licensing in and out. Fumio Suzuki, Ph.D., Corporate Technical Advisor, Kyowa Hakko Kogyo Co. Ltd.

Abstract not available at time of print. Please visit www.IBCLifeSciences. com/China for updates. Ravi Sodha, Ph.D., Head, Business Development, Emerging Markets, Global Business Development & Licensing, Novartis Pharma AG

12:30 Emerging Intellectual Life-Science Properties in Asia - the Boehringer Ingelheim In-Licensing Approach

Why Licensing? What are the latest trends regarding the emergence of intellectual life-science properties in Asia? What is the BI In-Licensing approach to East Asia? Real Cases: exisiting BI Global Partnerships with East Asian companies: Japan & Taiwan. Richard Gerstenberg, Ph.D., Operating Officer and Division Head, Nippon Boehringer Ingelheim

12:55 Networking Luncheon

12:55 Networking Luncheon

Media Partners For more information about these media partners or to become a media partner, please contact: In US/Europe: : Ellen Cabral: [email protected] In Asia-Pacific: Alison McInerney: [email protected]

SCRIP World Pharmaceutical News www.scrippharma.com Taylor & Francis www.taylorandfrancisgroup.com General Biologic www.generalbiologic.com Asia Pacific Biotech News www.asiabiotech.com BioPharmaLife www.mmgworldwide.biz.com

7

BioMelbourne Network www.biomelbourne.org BioSpectrumAsia www.biospectrumindia.com BioTechniques® www.biotechniques.com BioProcess International™ www.bioprocessintl.com BioExecutive International™ www.bioexecutiveintl.com CanBiotech www.canbiotech.com

D&MD Publications www.drugandmarket.com Global Information, Inc. www.infoshop-japan.com Good Clinical Practice Journal (GCPj) www.pjbpubs.com/gcpj/index.htm Pacific Genuity www.pacificgenuity.com PharmaAsia www.pharmaasia.com Pharma China www.pharmachinaonline.com

To Register, Web: www.IBCLifeSciences.com/China



Main Conference Clinical Trials 2:00 Opening Remarks by Chairperson

Paul Dai, M.D., Head of ICRO, Novartis China

PANEL DISCUSSION

2:05 Issues with Clinical Research in China

Focus on the current issues and share all the "think-out-of-the-box" ideas from different perspectives primarily because the "one size fits all" approach doesn't make sense any more in this market as the clinical research business is growing so fast and becomes so diverse. Discussion points include: External: • Regulatory application • Site selection • Investigator training and qualification • Communications between MNCs and CROs Internal: • People & Team Development • Communications with HQ • Infrastructure • System and process improvement • Quality control and assurance Moderator: Paul Dai, M.D., Head of ICRO, Novartis China Panelists: Frank Fan, Ph.D., Medical Director, China/HK, Abbott Laboratories Qing An Jiao, M.D., Head of Asia Pacific, Director Clinical Operations, Global Clinical Development, MDS Pharma Services (China) Inc Ling Su, Ph.D., Medical & International Pharma Development Director, Shanghai Roche Pharmaceuticals Ltd. Ning Xu, M.D., MBA, Medical Director / Medical Affairs and Clinical Operations, GSK Tianjin Smith Kline & French Laboratories Mark Engel, J.D., Chairman, Excel PharmaStudies

3:00 Patient Recruitment – Requiring New Skills and Mindset from Clinical Research Staff

China is not anymore a country full of unlimited patient resources. Patient recruitment becomes more and more challenging to many sponsors, especially, when many clinical trials require patients with very unique disease profile or specific treatment window. Oncology clinical trials have been increased significantly in China. Competitions among different sponsors for cancer patients resulted in the difficulty in recruiting oncology patients. I would like to share some of my thoughts and observation in planning and implementation of patient recruitment campaign. Clinical research people need marketing and sales concept to develop patient recruitment activities. Carol Zhu, B. Sci., MBA, Head of National Clinical Operations, GSK China Pharmaceuticals

3:25 Optimizing Return on Investment (ROI) of Multinational and Domestic Clinical Trials in China

Abstract not available at time of print. Please visit www.IBCLifeSciences.com/China for updates. Min Irwin, M.D., Ph.D., Medical Head of China, Medical & Scientific Affairs, Bayer Healthcare Co. Ltd.

3:50 Afternoon Refreshments in Exhibit Hall 4:30 Building Clinical Trial Infrastructure in General Hospitals

China has been rapidly emerging as a clinical and biomedical research location in the last 10 years. Both multinational drug firms and contract research organizations are conducting global clinical trials in China in compliance with ICH GCP guidelines. The quality of high standard clinical trials depends not only on the competent clinical investigators but also on the clinical trial infrastructure at the general hospitals or academic institutions. A gap still exists in China between the clinical trial quality expectation and current infrastructure of clinical research in the general hospitals. Setting up a clinical research unit in the general hospitals is a complex process. The following aspects should be clearly defined and established: Institutional Review Board, governance, organization, standard operating procedures, administration, logistics, quality assurance system, training and educations. A case study compares the operating model of clinical research units in the general hospitals of the United States, China and Hong Kong SAR. Frank Fan, M.D., Medical Director, China/HK, Abbott Laboratories

Wednesday, June 6, 2007 (continued) 4:55 Clinical Outsourcing Experience: Role of PM in Establishing and Managing Relationship between CROs and Sponsors High attrition rate and high development cost drive big pharmas to look for alternatives in carrying out development studies. The R&D services most commonly outsourced are clinical monitoring for Phase II-IV trials, clinical trial project management and data management. Overall, CROs are able to shorten clinical testing times by as much as 30%. Successful CROs develop strong relationship with Sponsor. Project managers play essential role in establishing and managing the relationship between CROs and sponsors. This talk will review best practices in establishing collaboration with CRO in conducting clinical study. These best practices will in turn improve team performance and shorten study time. Joanne Chen, Ph.D., Director, Global Project Management and Leadership, Daiichi-Sankyo Pharmaceutical

5:20 Managing Clinical Outsourcing Activities: From Sponsors’ Perspective

As more and more companies begin to include China as part of its global drug development, there are still concerns on how to manage risks associated with China operation, including, but limited to, quality risk, regulatory risk, IP risk and legal risk, etc. This discussion is intended to exam these issues from sponsor's perspective with primary focus on quality and regulatory concern. In addition, it would also suggest an approach to manage CRO operation in China including some necessary homework sponsor has to do n advance in order to maximize the value of conducing clinical study in China. The discussion will benefit sponsor's R&D head, outsourcing manager, and executives from Chinese CROs. Dan Zhang, Ph.D., Head, Clinical Development & Safety, Sigma-Tau

5:45 Close of Day Two 6:30 Cocktail Sunset Cruise Sponsored by

and

The Grand Acquaintance Cruise is reputed as the “Grand Hyatt on the Water” with its three-tier design, luxurious decoration and facilities. The cruise offers a panoramic view of the scenic two banks of Huangpu River, and its outdoor deck on the third floor offers an unrestricted view of the sea and the sky. What better way than to spend an evening of cocktail and drinks with business partners and acquaintances while enjoying the breeze and the spectacular scenery! (Free for first 100 attendees with a main conference registration. An additional fee of US$75 per attendee applies after the 100th person. Confirmation will be sent after registration. To sign up and reserve your spot, please check box on registration page.)

Conference & Exhibition Venue The 2nd Annual Drug Discovery Technology® conference & exhibition: China 2007 R&D Summit will be held at the

Grand Hyatt Shanghai

Jin Mao Tower, 88 Century Boulevard, Pudong, Shanghai 200121, People’s Republic of China Tel: +86-21-5049-1234 • Fax: +86-21-5049-8381 Grand Hyatt Shanghai is the 'highest hotel in the world' (53rd to 87th floors of the Jin Mao Tower), in the heart of Pudong, Shanghai's financial and business district, and with easy access to the Shanghai Stock Exchange, Shanghai World Financial Centre and the International Conference Centre. The hotel is just 50 minutes' drive from Pudong Airport .

E-mail: [email protected]• Call: (+65) 6514-3180 • Fax: (+65) 6733-5087

8



Main Conference

Thursday, June 7, 2007

The Rise of Biotechnology in China 8:45 Chairperson’s Opening Remarks

Yun He, Head, Discovery Chemistry, Roche China R&D Center

8:50 Featured Presentation The Rise of China’s Biotech and Opportunities for Partnership

In the last 6 years, GeneScience Pharmaceuticals Inc. has been growing at a speed of more than 60% annually and become the largest biopharmaceutical company in China now. This growth was due to a unique marketing and new product development strategy focusing on innovative biopharmaceuticals. GenSci is focusing on new formulation of existing biological products, such as PEGylation, sustain release and non-injectable formulation of proteins. Currently we have 10 innovative R&D programs in pipeline. GenSci’s new drug, Genfulin™, topical Molgramostim gel indicated for the treatment of wound healing, is expected to get approval by China's SFDA in early 2007. GenSci’s long-acting form of rhGH (PEG-GH) is on target to launch in 2008 in China, based on the positive results from Phase I and partial Phase II clinical trials. GenSci welcomes strategic partners to collaboratively develop international market in US, EU and emerging markets. The scope of collaborations includes GenSci’s current products in APIs and Finish Fills; GenSci’s current formulation technologies: PEGylation, suppository and topical forms. The approaches of collaborations can be contract manufacturing, co-applications or registration, co-marketing (distribution) or in-licensing and out-licensing. Lei Jin, Ph.D., Chief Executive Officer, GeneScience Pharmaceuticals Co. Ltd

Unique Biotech R&D Business Models 9:20 Making Innovative Medicines Faster and Cost-Efficiently

Ascenta Therapeutics is a privately-funded biotech company focused on discovering and developing new cancer therapies. In only three years, the company has gone from one preclinical-stage product to three preclinical programs and a product lead in several Phase 2 cancer clinical trials. This progress has been accomplished using multiple academic collaborations and outsourcing as well as establishing R&D center in China that the company believes can make new medicines faster and more cost-efficiently than in the past. This model has three key characteristics: 1) Early Discovery is Generated Externally (EDGE) via academic discovery alliances; 2) a Shanghai subsidiary and outsourcing efficiently progresses the pipeline through lead optimization, scale-up manufacturing and preclinical development; 3) Bicoastal US clinical trial site management offices (San Diego and Philadelphia) that can directly manage several multi-center Phase 1-2 cancer clinical trials at patient enrollment and expense efficiencies that surpass typical biotech outsourcing approaches. This presentation will illustrate the company’s business model, discuss its unique efficiencies and progress to date and outline plans for further expansion. Mel Sorenson, M.D., Ph.D., President & CEO, Ascenta Therapeutics

9:45 Technology Workshop The Birth and Evolution of an Innovative Biotech Hub: Suzhou Industrial Park’s BioBay

Abstract not available at time of print. Please visit www.IBCLIfeSciences. com/China for updates. Liu Yuwen, Executive Vice President, SIP Bio & Nano Technology Development Co., Ltd

10:10 Morning Refreshments in Exhibit Hall

9

10:40 Technology Workshop Accelerating the Drug Discovery Process by Automated Flash Chromatography

This presentation will introduce the CombiFlash Rf, a new automated flash chromatography instrument for drug discovery. This novel purification system can increase the productivity of a synthesis group by as much as 37%, as measured by the number of compounds purified in a typical week. This results in faster overall project progression and a reduction in costs per product purified. The authors will illustrate the use of this new instrument in the successful development of an optimized separation of a mixture of high pKa compounds using reverse phase specialty media Athos C. Rosselli, Manager, Asia Pacific, Teledyne Isco

11:05 Developing Innovative Pharmaceutical Products in China: A Tale of Two Countries

NOD Pharmaceuticals is pioneering a unique business model of developing truly innovative technology/products in China first followed by global, particularly US, markets. This model addresses the broken model of venture capital financing in the US market and allows development of enabling technology with contained risk. A detailed comparison between US and China in terms cost, efficiency, credibility, and market of pharmaceutical development will be presented. Using NOD as an example, the advantages of this business model is illustrated. The experiences and lessoned learned in the process of developing oral insulin formulations are shared. William Lee, Ph.D., Chief Executive Officer, NOD Pharmacetuicals, Inc.

11:30 Virtual Drug Discovery and Development – A Case Study Many small drug discovery and development companies are implementing leaner business models, outsourcing nearly all stages of discovery & development processes in response to escalating R&D and development costs. This business model has gained increasingly popularity within the industry. In this case study, I will report on my personal experience in deploying this business model and in forging strategic alignments with CROs. Several strategic outsourcing models such as fee for service, FTE and risk/reward sharing will be discussed. Zhengming Chen, Ph.D., Director of Chemistry, DOV Pharmaceutical, Inc.

12:00 End of Main Conference

1:00 Site Visit

(Free for first 100 attendees with a main conference registration)

Shanghai Biochip Co. Ltd., also known as SBC or ShanghaiBio, situated on a ten-acre campus in Zhangjiang Hi-Tech Park, with operations of global marketing and customer support at USA (MaxyBio Corporation), is one of the biotech giants that you are surely not to miss. ShanghaiBio/MaxyBio is currently collaborating with leading global pharma/biotech and CRO companies, and offering a complete spectrum of services ranging from early discovery to clinical trials. The site-tour will walk you through our major state of the facilities includes: Genomics/Proteomics/Pharmacogenomics Labs, Chemistry Lab, HT screening lab, Clinical Central Lab and tissue bank, etc. www. maxybio.com, or www.shbiochip.com (Additional fees may apply after the 100th person. Confirmation will be sent after registration. To sign up and reserve your spot, please check box on registration page.)

Interested to host a Site Visit? Opportunities are still available! For more information, please email Shubir Khattau, [email protected] or Sherry Johnson, [email protected]

To Register, Web: www.IBCLifeSciences.com/China



Sponsorship and Exhibition Information When you sponsor or exhibit at Drug Discovery Technology®: China 2007 R&D Summit, you will: • Gain international exposure through our specialized marketing campaign • Network with international players in the industry • Meet face-to-face with top-notch researchers and executives from pharmaceutical and biotechnology companies • Showcase your latest technology to our targeted audience of key decision-makers • Build invaluable relationships and form new partnerships that give you a competitive advantage in the US, Europe and Asia-Pacific

Asia-Pacific Sales Contact: Shubir Khattau: [email protected] • Tel.: +65-6835-5134 U.S. & Euro Sales Contact: Sherry Johnson: [email protected] • Tel.: +1-508-614-1451

Sponsors / Exhibitors Gold Sponsor

BioBay is the perfect location to start your career in the life-science field. This 213 acre R&D park is conveniently located in the China-Singapore Suzhou Industrial Park. We provide excellent quality facilities and services, with a first-class innovation environment, strong government support, a mature capital security system, a seed fund & Biopharma incubator, and professional public technical platforms and comprehensive service solutions. If you are interested in BioBay or would like more information, BioBay welcomes you to take a closer look.

Silver and Luncheon Sponsor Pfizer Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals. The innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. Our products are available in more than 150 countries. Pfizer Global Research & Development (PGRD) is one of the world’s largest private biomedical R&D organizations. Its mission is to conduct biomedical and scientific research through drug discovery and development process on a wide range of diseases. Pfizer Global R&D has facilities around the world including the Pfizer China Research & Development Center, located in Shanghai, China.

Silver Sponsor

William Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, we have been committed to helping clients achieve their financial objectives. As an independent, employee-owned firm, our philosophy is to serve our clients' interests first and foremost. We place a high value on the enduring nature of our client relationships, the quality of our products and services, and the continuity and integrity of our people. William Blair & Company has offices in Chicago, Boston, Hartford, London, San Francisco, Tokyo, Vaduz, and Zurich. For more information, please visit www.williamblair.com.

Featured Sponsor

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription

10

pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $26.5 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is committed to the discovery and development of innovative, effective medicines and spends over $15 million every working day on the research and development of new medicines that meet patient needs. The R&D organization is comprised of approximately 12,000 people located in seven countries.

Session Sponsor Bridge provides GLP compliant preclinical contract research services in the US and China. Services include General Toxicology, Reproductive and Developmental Toxicology (DART), Safety Pharmacology, DMPK, Carcinogenicity testing and Vaccine Development in support of IND and NDA submissions. Studies are backed by in-house bioanalytical chemistry, histopathology, and clinical pathology capabilities.

Corporate Sponsor Ernst & Young, a global leader in professional services, is committed to restoring the public's trust in professional services firms and in the quality of financial reporting. Its 114,000 people in 140 countries pursue the highest levels of integrity, quality, and professionalism in providing a range of sophisticated services centered on our core competencies of auditing, accounting, tax, and transactions. Further information about Ernst & Young and its approach to a variety of business issues can be found at www.ey.com/ perspectives. Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited does not provide services to clients.

Bronze Sponsors Fidelity is a global pioneer in venture capital, having invested over US$ 600 million of its own proprietary capital in the US, Asia and Europe over the past 35 years. Fidelity Asia Ventures invests in both technology and healthcare in Asia. Fidelity Biosciences focuses on life sciences opportunities in the United States. www.fidelityasiaventures.com Elsevier MDL provides integrated informatics, database and workflow software and services that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision-making and shortening cycle times. MDL discovery informatics solutions are augmented by 400 Elsevier chemistry and life sciences journals and related products. Visit www.mdl.com Shanghai ChemPartner Co., Ltd., founded in April, 2003, is a wholly owned subsidiary of ChemPartner Holding Company. ChemPartner is located in Shanghai Zhangjiang Hi-tech Park. ChemPartner mainly provides R&D services in the areas of combinatorial chemistry, medicinal chemistry and process chemistry. Quality assurance tests on pharmaceutical or chemical products are also the services that we provide for our domestic and international clients.

Technology Workshop Sponsor TELEDYNE ISCO is a leading manufacturer of advanced scientific instruments and water quality products for professionals working in the pharmaceutical, chemical, petroleum, academic and environmental fields. Our products are focused on reducing costs through increased productivity and efficiency. TELEDYNE ISCO products are available globally through an extensive, factory –supported network of distributors and representatives.

Featured Exhibitor

To Register, Web: www.IBCLifeSciences.com/China



2nd International Conference & Exhibition Drug Discovery Technology®

China 2007 R&D Summit

Partnering, Licensing & Outsourcing from R&D to Clinical Trials June 4-7, 2007 • Grand Hyatt Hotel • Shanghai China q Please register me for Drug Discovery Technology®: China 2007 R&D Summit

NAME

R4163fax

JOB TITLE

E-MAIL q Yes, I would like to receive occasional e-mail messages and offers from other organizations. ORGANIZATION

DEPARTMENT

MAILING ADDRESS

Team Discount:

CITY

STATE

TELEPHONE

POSTAL CODE

FAX

Register 3, the 4th goes FREE!

COUNTRY

APPROVING MANAGER

Data Protection: The personal information shown on this form, and/or provided by you, will be held on a database and may be shared with companies in the Informa group in the UK and internationally. Sometimes your details may be obtained from, or made available to, external companies for marketing purposes. If you do not wish for your details to be used for this purpose, please email [email protected].



On or before March 9, 2007

On or before April 6, 2007

On or before May 4, 2007

After May 4, 2007

o US$749 o US$1149 o US$1549

o US$799 o US$1199 o US$1599

o US$899 o US$1299 o US$1699

o US$999 o US$1399 o US$1799

o US$949 o US$1349 o US$1749

o US$999 o US$1399 o US$1799

o US$1099 o US$1499 o US$1899

o US$1199 o US$1599 o US$1999

o US$249 o US$349 o US$449 On or before March 9, 2007

o US$299 o US$399 o US$499 On or before April 6, 2007

o US$399 o US$499 o US$599 On or before May 4, 2007

o US$499 o US$599 o US$699 After May 4, 2007

China-Based Academic/Government Institutions o US$349 International Institutions Outside China o US$749

o US$399 o US$799

o US$499 o US$899

o US$599 o US$999

o US$449 o US$949

o US$499 o US$999

o US$599 o US$1099

o US$699 o US$1199

o US$199 o US$299

o US$199 o US$299

o US$299 o US$399

o US$299 o US$399

Industry Fees Main Conference Only (Tue-Thur)

Wholly-owned Chinese Companies International Companies based in China International Companies outside China

Main Conference plus Pre-Conference Workshop (Mon-Thur) Wholly-owned Chinese Companies International Companies based in China International Companies outside China Pre-Conference Workshop only (Mon) Wholly-owned Chinese Companies International Companies based in China International Companies outside China

Academic/Government* Fees Main Conference Only (Tue-Thur)

Main Conference plus Pre-Conference Workshop (Mon-Thur) China-Based Academic/Government Institutions International Institutions Outside China Pre-Conference Workshop only (Mon) China-Based Academic/Government Institutions International Institutions Outside China

Gala Dinner

o US$100

Cocktail Sunset Cruise Site Visit

Online: www.IBCLifeSciences.com/China Mail:  IBC Asia (S) PTE LTD No. 1 Grange Road #08-02 Orchard Building Singapore 239693 Phone: +65 6835 5136 Fax: +65 6733 5087 Email: [email protected]

o Free for first 100 attendees with a main conference registration

o Free for first 100 attendees with a main conference registration

*Academic/Government rate is extended to full-time employees of government, universities, and university-affiliated hospitals only. Prices include lunch, refreshments and speaker documentation. For security precautions, a photo identification will be required of ALL attendees at check-in. For on-site registrations, please add US$100 Unable to Attend? Purchase the Conference CD-ROM. This comprehensive selection of bound “hot off the press” information will be available four weeks after the conference. o I cannot attend. Please send ______ Main Conference CD-ROM(s). Enclosed is my payment for US$399 each, plus shipping and handling (US$25 in the U.S., US$45 outside the U.S.).

Payment Information Payment is required in advance of the conference r Mastercard r Visa r American Express r Check r Wire Transfer

Total: US$_____________

Payments by US$ bank draft or cheque to be made in favour of IBC Asia (S) Pte Ltd’ payable in Singapore. Payment by telegraphic transfer in US$ must be made to IBC Asia (S) Pte Ltd – A/C No: 147-059513-001 (SGD) – A/C No: 260-457866-178 (USD) The Hong Kong and Shanghai Banking Corporation Limited, 21 Collyer Quay, HSBC Building, Singapore 049320 Card #

Exp. Date

Name (as appears on card)

Signature

When three members of the same company register for the conference at the same time, the fourth attends for FREE! Complete registration forms for all parties must be sent together with complete payments for the entire group to qualify for team discounts. No partial payments or registrations sent without payment are eligible for this discount. Note: The free registration will be applied to the lowest conference fee option.

Hotel and Transportation Reservations Special room rates have been contracted at the Grand Hyatt Shanghai for IBC’s delegation. To take advantage of this special rate, please visit the conference website at www.IBCLifeSciences.com/China, select Hotel Info link to download the reservation form and fax to the hotel directly. The hotel can also arrange ground transfer between airport/hotel. Please indicate your request on the hotel reservation form. For questions on conference venue, hotel reservations and transportation, please contact Kerina Chua at [email protected] CONFERENCE REGISTRATION SUBSTITUTIONS/ CANCELLATIONS: In order to receive a prompt refund, your notice of cancellation must be received in writing (by letter or fax) by May 9, 2007. We regret cancellations will not be accepted after that date. However, we will be pleased to transfer your registration to another member of your company at any time. If you plan to send someone in your place, please notify us as soon as possible so that materials can be prepared. All cancellations will be subject to a US$399 processing fee. If IBC cancels an event, IBC is not responsible for any airfare, hotel or other costs incurred by registrants. Speakers subject to change without notice.

Travel/Visa Information PLEASE NOTE: Visas are required for some nationalities to travel to China for this conference. Please contact your travel agent and/or the Chinese Consulate/Embassy in your country for exact details and visa application procedures as soon as possible. Visa processing times can vary.

E-mail: [email protected]• Call: (+65) 6514-3180 • Fax: (+65) 6733-5087

11